Company intelligence / Profile preview

Avila Therapeutics

Bedford, Massachusetts, United Statesatlasventure.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Avila Therapeutics developed a proprietary platform for creating covalent drugs that irreversibly bind to disease-causing proteins. Their approach, termed "protein silencing," aimed to deliver highly effective therapies for cancers, autoimmune diseases, and viral infections. The company advanced several programs into preclinical and early clinical stages before being acquired.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small molecules (specifically covalent drugs)[1][5][6]
Industry: Biotech

Partnerships

Novartis Option Fund participated as an investor with potential strategic interest[5].

Beyond the preview

Go deeper on Avila Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avila Therapeutics.

Explore the full profile